ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents
ADC Therapeutics has announced the dosing of the first patient in the LOTIS-7 Phase 1b clinical trial, examining the efficacy of ZYNLONTA in combination with polatuzumab vedotin for treating relapsed or refractory B-cell non-Hodgkin lymphoma.
The trial aims to evaluate ZYNLONTA's safety and activity against various types of B-cell lymphomas, with a focus on achieving better responses in patients. This trial follows promising preclinical studies that indicated potential synergies with other therapies.
- First patient dosed in LOTIS-7 Phase 1b trial for ZYNLONTA.
- Trial explores combination therapy with polatuzumab vedotin, potentially enhancing treatment outcomes for B-cell lymphoma.
- ZYNLONTA has shown synergistic effects in preclinical studies.
- None.
Opportunity to enhance outcomes in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
First arm of trial to evaluate ZYNLONTA in combination with polatuzumab vedotin
LAUSANNE,
“As ZYNLONTA has been shown in preclinical studies to have synergistic or additive effects when combined with other anti-cancer therapies, we are eager to explore the potential of our differentiated CD19-directed ADC in combination with other established therapies,” said
The first arm of the
ZYNLONTA is also being evaluated in the LOTIS clinical trial program as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy. For more information about the LOTIS trials, please visit https://www.adctherapeutics.com/our-pipeline/#lonca.
About ZYNLONTA® (loncastuximab tesirine-lpyl)
ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death.
The
ZYNLONTA is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy.
About
ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami,
ZYNLONTA® is a registered trademark of
Forward-Looking Statements
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business and commercialization strategy, market opportunities, products and product candidates, research pipeline, ongoing and planned preclinical studies and clinical trials, regulatory submissions and approvals, projected revenues and expenses and the timing of revenues and expenses, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20220629005089/en/
Investors
Eugenia.Litz@adctherapeutics.com
+44 7879 627205
amanda.hamilton@adctherapeutics.com
+1 917-288-7023
Media
maryann.ondish@adctherapeutics.com
Tel.: +1 914-552-4625
Source:
FAQ
What is the LOTIS-7 trial for ADC Therapeutics (ADCT)?
What is ZYNLONTA's mechanism of action?
What types of lymphoma are being studied in the LOTIS-7 trial?
What are the next steps after the LOTIS-7 trial?